Epstein Barr Virus: Development of Vaccines and Immune Cell Therapy for EBV-Associated Diseases. PMID: 34691042
Protective anti-gB neutralizing antibodies targeting two vulnerable sites for EBV-cell membrane fusion. PMID: 35917353
Ephrin receptor A2 is an epithelial cell receptor for Epstein-Barr virus entry. PMID: 29292383
The COMPLEXity in herpesvirus entry. PMID: 28538165
Mapping regions of Epstein-Barr virus (EBV) glycoprotein B (gB) important for fusion function with gH/gL. PMID: 21376360
HCMV gB shares structural and functional properties with gB proteins from other herpesviruses. PMID: 23089254
Metastatic disease in head & neck oncology. PMID: 32469009
gH/gL supercomplexes at early stages of herpesvirus entry. PMID: 26849495
Glycoprotein B Antibodies Completely Neutralize EBV Infection of B Cells. PMID: 35711430
Integrins as Herpesvirus Receptors and Mediators of the Host Signalosome. PMID: 27501260
Vesicular Stomatitis Virus-Based Epstein-Barr Virus Vaccines Elicit Strong Protective Immune Responses. PMID: 35404082
Structural and Mechanistic Insights into the Tropism of Epstein-Barr Virus. PMID: 27094060
Modulation of Epstein-Barr virus glycoprotein B (gB) fusion activity by the gB cytoplasmic tail domain. PMID: 23341550
Characterization of EBV gB indicates properties of both class I and class II viral fusion proteins. PMID: 17655906
Stuck in the middle: structural insights into the role of the gH/gL heterodimer in herpesvirus entry. PMID: 23107819
Epstein-Barr Virus Fusion with Epithelial Cells Triggered by gB Is Restricted by a gL Glycosylation Site. PMID: 28956769
Functional analysis of glycoprotein L (gL) from rhesus lymphocryptovirus in Epstein-Barr virus-mediated cell fusion indicates a direct role of gL in gB-induced membrane fusion. PMID: 19457993
Potential entry receptors for human γ-herpesvirus into epithelial cells: A plausible therapeutic target for viral infections. PMID: 34800753
Integrins as triggers of Epstein-Barr virus fusion and epithelial cell infection. PMID: 21178476
Epstein-Barr virus glycoprotein gB and gHgL can mediate fusion and entry in trans, and heat can act as a partial surrogate for gHgL and trigger a conformational change in gB. PMID: 25142593
Characterization of murine gammaherpesvirus 68 glycoprotein B (gB) homolog: similarity to Epstein-Barr virus gB (gp110). PMID: 8083987
Inhibition of EBV-mediated membrane fusion by anti-gHgL antibodies. PMID: 28939750
The fusion loops and membrane proximal region of Epstein-Barr virus glycoprotein B (gB) can function in the context of herpes simplex virus 1 gB when substituted individually but not in combination. PMID: 23089849
Failure to complement infectivity of EBV and HSV-1 glycoprotein B (gB) deletion mutants with gBs from different human herpesvirus subfamilies. PMID: 9344919
Rabbits immunized with Epstein-Barr virus gH/gL or gB recombinant proteins elicit higher serum virus neutralizing activity than gp350. PMID: 27291087
Structure of a trimeric variant of the Epstein-Barr virus glycoprotein B. PMID: 19196955
Analysis of Epstein-Barr virus glycoprotein B functional domains via linker insertion mutagenesis. PMID: 18987135
Epstein-Barr virus activates F-box protein FBXO2 to limit viral infectivity by targeting glycoprotein B for degradation. PMID: 30052682
Novel Epstein-Barr virus-like particles incorporating gH/gL-EBNA1 or gB-LMP2 induce high neutralizing antibody titers and EBV-specific T-cell responses in immunized mice. PMID: 27926486
Predictors of Epstein-Barr virus serostatus in young people in England. PMID: 31779585
Epstein-Barr virus glycoprotein homologous to herpes simplex virus gB. PMID: 3027378
Cleavage of Epstein-Barr virus glycoprotein B is required for full function in cell-cell fusion with both epithelial and B cells. PMID: 19218203
HLA-DR and HLA-DP restricted epitopes from human cytomegalovirus glycoprotein B recognized by CD4+ T-cell clones from chronically infected individuals. PMID: 22797815
[The entry of Epstein-Barr virus into B lymphocytes and epithelial cells during infection]. PMID: 25272606
Four Decades of Prophylactic EBV Vaccine Research: A Systematic Review and Historical Perspective. PMID: 35493498
Glycoprotein B of bovine herpesvirus type 4: its phylogenetic relationship to gB equivalents of the herpesviruses. PMID: 7871762
Rapid Generation of TCR and CD8αβ Transgenic Virus Specific T Cells for Immunotherapy of Leukemia. PMID: 35572604
Robust Benchmark Structural Variant Calls of An Asian Using State-of-the-art Long-read Sequencing Technologies. PMID: 33662625
The Epstein-Barr virus (EBV) glycoprotein B cytoplasmic C-terminal tail domain regulates the energy requirement for EBV-induced membrane fusion. PMID: 25100836
Human Cytomegalovirus and Epstein-Barr virus specific immunity in patients with ulcerative colitis. PMID: 33772380
Human Cytomegalovirus and Epstein-Barr Virus Genotypes in Apical Periodontitis Lesions. PMID: 26435468
Proteins of purified Epstein-Barr virus. PMID: 15534216
Functional cross-reactivity between the glycoprotein B of herpes simplex virus type 1 and Epstein-Barr virus. PMID: 15493256
Multiple Sclerosis Pathogenesis: Possible Interplay between Vitamin D Status and Epstein Barr Virus Infection. PMID: 36722238
A Liposome-Based Nanoparticle Vaccine Induces Effective Immunity Against EBV Infection., PMID:40338258
Structure and Antigenicity of Kaposi's Sarcoma-Associated Herpesvirus Glycoprotein B., PMID:40285648
A Chimeric Virus-Like Particle Vaccine Presenting an Immunodominant Epitope of gB Elicited Potent Neutralizing Antibodies against EBV Infection In Vitro and In Vivo., PMID:40272901
An insect cell-derived extracellular vesicle-based gB vaccine elicits robust adaptive immune responses against Epstein-Barr virus., PMID:39499444
Multivalent MVA-vectored vaccine elicits EBV neutralizing antibodies in rhesus macaques that reduce EBV infection in humanized mice., PMID:39346922
GB and gH/gL fusion machinery: a promising target for vaccines to prevent Epstein-Barr virus infection., PMID:39020055
Cytomegalovirus, Epstein-Barr Virus, Herpes Simplex Virus, and Varicella Zoster Virus Infection Dynamics in People with Multiple Sclerosis from Northern Italy., PMID:38921797
A cocktail nanovaccine targeting key entry glycoproteins elicits high neutralizing antibody levels against EBV infection., PMID:38906867
Twenty-four Month Outcomes of Extended- Versus Standard-course Antibiotic Therapy in Children Hospitalized With Pneumonia in High-risk Settings: A Randomized Controlled Trial., PMID:38830139
Evaluation of serum Epstein-Barr virus envelope glycoproteins antibodies and their association with systemic autoimmune diseases., PMID:38587217
Fully Human Herpesvirus-Specific Neutralizing IgG Antibodies Generated by EBV Immortalization of Splenocytes-Derived from Immunized Humanized Mice., PMID:38201224
A gB nanoparticle vaccine elicits a protective neutralizing antibody response against EBV., PMID:37848029
Epstein-Barr Virus Glycoprotein Antibody Titers and Risk of Nasopharyngeal Carcinoma., PMID:36519117
Urgency and necessity of Epstein-Barr virus prophylactic vaccines., PMID:36494369
Protective anti-gB neutralizing antibodies targeting two vulnerable sites for EBV-cell membrane fusion., PMID:35917353
Glycoprotein B Antibodies Completely Neutralize EBV Infection of B Cells., PMID:35711430
Four Decades of Prophylactic EBV Vaccine Research: A Systematic Review and Historical Perspective., PMID:35493498
Vesicular Stomatitis Virus-Based Epstein-Barr Virus Vaccines Elicit Strong Protective Immune Responses., PMID:35404082
Epstein Barr Virus: Development of Vaccines and Immune Cell Therapy for EBV-Associated Diseases., PMID:34691042
Immunization with Epstein-Barr Virus Core Fusion Machinery Envelope Proteins Elicit High Titers of Neutralizing Activities and Protect Humanized Mice from Lethal Dose EBV Challenge., PMID:33808755
Identification of two highly antigenic epitope markers predicting multiple sclerosis in optic neuritis patients., PMID:33493797
Association between Antibody Responses to Epstein-Barr Virus Glycoproteins, Neutralization of Infectivity, and the Risk of Nasopharyngeal Carcinoma., PMID:33268566
A Pentavalent Epstein-Barr Virus-Like Particle Vaccine Elicits High Titers of Neutralizing Antibodies against Epstein-Barr Virus Infection in Immunized Rabbits., PMID:32268575
Predictors of Epstein-Barr virus serostatus in young people in England., PMID:31779585
Epstein-Barr virus infection with acute acalculous cholecystitis in previously healthy children., PMID:31243873
Increased antibody levels to stage-specific Epstein-Barr virus antigens in systemic autoimmune diseases reveal a common pathology., PMID:30727744
Acidic pH Mediates Changes in Antigenic and Oligomeric Conformation of Herpes Simplex Virus gB and Is a Determinant of Cell-Specific Entry., PMID:29925660
An Antibody Targeting the Fusion Machinery Neutralizes Dual-Tropic Infection and Defines a Site of Vulnerability on Epstein-Barr Virus., PMID:29669253
Ephrin receptor A2 is an epithelial cell receptor for Epstein-Barr virus entry., PMID:29292383
Inhibition of EBV-mediated membrane fusion by anti-gHgL antibodies., PMID:28939750
Novel Epstein-Barr virus-like particles incorporating gH/gL-EBNA1 or gB-LMP2 induce high neutralizing antibody titers and EBV-specific T-cell responses in immunized mice., PMID:27926486
Cerebrospinal fluid anti-Epstein-Barr virus specific oligoclonal IgM and IgG bands in patients with clinically isolated and Guillain-Barré syndrome., PMID:27878471
Rabbits immunized with Epstein-Barr virus gH/gL or gB recombinant proteins elicit higher serum virus neutralizing activity than gp350., PMID:27291087
Early T Cell Recognition of B Cells following Epstein-Barr Virus Infection: Identifying Potential Targets for Prophylactic Vaccination., PMID:27096949
Scanning Mutagenesis of Human Cytomegalovirus Glycoprotein gH/gL., PMID:26656708
Crystal Structure of the Human Cytomegalovirus Glycoprotein B., PMID:26484870
Human Cytomegalovirus gH/gL/gO Promotes the Fusion Step of Entry into All Cell Types, whereas gH/gL/UL128-131 Broadens Virus Tropism through a Distinct Mechanism., PMID:26085146
The use of humoral responses as a marker of CMV burden in HIV patients on ART requires consideration of T-cell recovery and persistent B-cell activation., PMID:25506120
Herpes virus fusion and entry: a story with many characters., PMID:22754650
Fusion of Epstein-Barr virus with epithelial cells can be triggered by αvβ5 in addition to αvβ6 and αvβ8, and integrin binding triggers a conformational change in glycoproteins gHgL., PMID:21957301
Epithelial cell retention of transcriptionally active, P3HR-1-derived heterogeneous Epstein-Barr virus DNA with concurrent loss of parental virus., PMID:21593154
Structure of a core fragment of glycoprotein H from pseudorabies virus in complex with antibody., PMID:21149698
Infection of porcine cells with human herpesviruses., PMID:20692426
Fusion of epithelial cells by Epstein-Barr virus proteins is triggered by binding of viral glycoproteins gHgL to integrins alphavbeta6 or alphavbeta8., PMID:19920174
Prevalence of persistent and latent viruses in untreated patients infected with HIV-1 from Ghana, West Africa., PMID:19774687
Viral reactivation is not related to septic complications after major surgical resections., PMID:18397464
Point mutations in EBV gH that abrogate or differentially affect B cell and epithelial cell fusion., PMID:17307213
Identification of tear lipocalin as a novel autoantigen target in Sjögren's syndrome., PMID:16249071
Mutations of Epstein-Barr virus gH that are differentially able to support fusion with B cells or epithelial cells., PMID:16103144
Cell-surface expression of a mutated Epstein-Barr virus glycoprotein B allows fusion independent of other viral proteins., PMID:15583133
For research use only. Not for human or drug use.
